Recombinant Human LGALS3, His-tagged
Cat.No. : | LGALS3-222H |
Product Overview : | Recombinant Human LGALS3 encoding the human Galectin 3 (Met1-Ile250P) was recombined with his tag at the N Terminus. That was expressed inE.Coli,and purified by Ni-NTA Column. MW=26.2 KD. |
- Specification
- Gene Information
- Related Products
Cat. No. : | LGALS3-222H |
Description : | Lectins, of either plant or animal origin, are carbohydrate binding proteins that interact with glycoprotein and glycolipids on the surface of animal cells. The Galectins are lectins that recognize and interact with beta-galactoside moieties. Galactin-3 regulates a number of biological processes, including embryogenesis, inflammatory responses, cell progression and metastasis. Galectin-3 is normally expressed in epithelia of a variety of tissues, including colon and endometrium, and in various inflammatory cells, including macrophages. |
Source : | E. Coli. |
Sequence : | Human Galectin-3 (Met1- Ile250P)1MADNFSLHDA LSGSGNPNPQ GWPGAWGNQP AGAGGYPGAS YPGAYPGQAP PGAYPGQAPP GAYPGAPGAY PGAPAPGVYP GPPSGPGAYP SSGQPSATGA YPATGPYGAP AGPLIVPYNL PLPGGVVPRM LITILGTVKP NANRIALDFQ RGNDVAFHFN PRFNENNRRV IVCNTKLDNN WGREERQSVF PFESGKPFKI QVLVEPDHFK VAVNDAHLLQ YNHRVKKLNE ISKLGISGDI DLTSASYTMI 250. |
Purity : | >95% in SDS gel. |
Formulation : | Lyophilized 100 μg human Galectin 3 in 50 μl of TBS (20 mM Tris, 50mM NaCl, pH8.0). Carry free. |
Application : | Cell biology, ELISA. |
Reconstitution : | Add 500 μl deionized water to the vial to prepare a working stock solution at 200μg/mL. Allow to set at least 30 minutes at 4°C, mix well. |
Storage : | Store lyophilized protein at -20°C or -70°C. Lyophilized protein is stable for up to 6 months from date of receipt at -70°C. Upon reconstitution, this protein can be stored at for a few weeks or at -70°C in a manual defrost freezer for long term storage (six months). Aliquot reconstituted protein to avoid repeated freezing / thawing cycles. |
Gene Name : | LGALS3 lectin, galactoside-binding, soluble, 3 [ Canis lupus familiaris ] |
Synonyms : | LGALS3;lectin, galactoside-binding, soluble, 3; Galectin-3; beta-galactosides-binding lectin; lectin, galactoside-binding, soluble, 3 (galectin 3) |
Gene ID : | 404021 |
UniProt ID : | P38486 |
Products Types
◆ Recombinant Protein | ||
LGALS3-191H | Active Recombinant Human LGALS3 Protein (Ala2-Ile250), N-His tagged, Animal-free, Carrier-free | +Inquiry |
LGALS3-1089H | Recombinant Human LGALS3 Protein, His-tagged | +Inquiry |
LGALS3-3622H | Recombinant Human LGALS3 | +Inquiry |
LGALS3-2322R | Recombinant Rhesus Macaque LGALS3 Protein, His (Fc)-Avi-tagged | +Inquiry |
LGALS3-2677H | Recombinant Human LGALS3 protein(91-250 aa), C-His-tagged | +Inquiry |
◆ Lysates | ||
LGALS3-4766HCL | Recombinant Human LGALS3 293 Cell Lysate | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (7)
Ask a questionLGALS3 has been investigated as a potential diagnostic and prognostic marker in various types of cancer. Its expression levels have been correlated with tumor stage, grade, and patient survival. LGALS3 can be detected in blood, urine, and tissue samples, making it a promising biomarker for non-invasive cancer detection and monitoring. Additionally, LGALS3 expression patterns, subcellular localization, and glycosylation status have been associated with specific cancer subtypes and clinical outcomes, providing insights into disease progression and patient prognosis.
The expression of LGALS3 is regulated at multiple levels, including transcriptional, post-transcriptional, and post-translational regulation. Transcription factors, such as Sp1, AP-1, and NF-κB, bind to the promoter region of the LGALS3 gene and regulate its expression. Epigenetic modifications, including DNA methylation and histone acetylation, can also influence LGALS3 expression. Additionally, microRNAs and RNA-binding proteins can regulate the stability and translation of LGALS3 mRNA. Moreover, various extracellular signals, such as cytokines and growth factors, can modulate LGALS3 expression in a tissue-specific and context-dependent manner.
LGALS3, also known as galectin-3, is a multifunctional protein involved in various cellular processes. It plays a role in cell adhesion, migration, apoptosis, immune response, and inflammation. LGALS3 can interact with glycosylated proteins and lipids, modulating their functions and signaling pathways. It also acts as a receptor for extracellular matrix proteins and plays a role in tissue remodeling. Additionally, LGALS3 has been implicated in cancer progression and metastasis, as well as in the regulation of fibrosis and wound healing.
Targeting LGALS3 has emerged as a potential therapeutic strategy in cancer treatment. Inhibition of LGALS3 expression or activity can impede tumor cell survival, migration, and invasion. Additionally, blocking LGALS3-mediated immune evasion mechanisms could enhance anti-tumor immune responses. Various approaches, such as small molecule inhibitors, antibodies, and gene silencing techniques, have been explored to target LGALS3 in preclinical and clinical studies. However, further research is needed to optimize these strategies and evaluate their efficacy and safety in cancer patients.
LGALS3 plays a critical role in immune response and inflammation. It can modulate the activation and function of immune cells, including macrophages, dendritic cells, and T cells. LGALS3 can promote cell adhesion and migration, facilitating immune cell recruitment to sites of inflammation. It also regulates the production of pro-inflammatory cytokines and chemokines, and can act as a chemoattractant for immune cells. Additionally, LGALS3 can modulate the clearance of apoptotic cells and regulate the resolution of inflammation.
LGALS3 contains a conserved carbohydrate recognition domain (CRD) that allows it to bind to glycosylated proteins and lipids. The CRD is responsible for LGALS3's interaction with specific glycan structures, mediating its diverse functions. LGALS3 also has a N-terminal domain involved in protein-protein interactions and a C-terminal domain that regulates its oligomerization. Moreover, LGALS3 can undergo post-translational modifications, such as phosphorylation and glycosylation, which can affect its localization, stability, and function.
LGALS3 has been implicated in various aspects of cancer progression and metastasis. It can promote tumor cell survival, migration, invasion, and angiogenesis. LGALS3 is involved in the modulation of epithelial-mesenchymal transition (EMT), a process essential for cancer cell metastasis. It also interacts with components of the extracellular matrix, promoting tumor cell adhesion and invasion. Furthermore, LGALS3 can influence immune evasion mechanisms employed by cancer cells, contributing to tumor immune escape and resistance to therapy.
Customer Reviews (3)
Write a reviewMy experimentation flourishes, as if guided by the hands of magic, all thanks to this extraordinary reagent.
Compared to similar products, this reagent demonstrates superior cost-effectiveness, satisfying both in terms of quality and price.
The storage conditions for the reagent are simple and do not require special storage environments.
Ask a Question for All LGALS3 Products
Required fields are marked with *
My Review for All LGALS3 Products
Required fields are marked with *
Inquiry Basket